CYP2D6 genotyping and the clinical impact on outcomes in breast cancer tamoxifen-treated patients.
Per Med
; 20(6): 477-483, 2023 Nov.
Article
in En
| MEDLINE
| ID: mdl-37947089
ABSTRACT
Aims:
To report the distribution of allele frequencies of CYP2D6 gene and to evaluate their influence on the clinical outcomes of a group of breast cancer patients receiving adjuvant tamoxifen treatment from Uruguay. Patients &methods:
199 samples were genotyped through real-time polymerase chain reaction assays. Metabolization profiles were inferred from the genotypes. Correlations were evaluated using Pearson's χ2 test.Results:
Phenotype frequencies were 0.65 normal (NM), 0.30 intermediate (IM) and 0.05 poor metabolizers (PM). Similar clinical outcomes between NM and (PM + IM) patient groups (odds ratio = 1.011, 95% CI = 0.2703-3.7826; p = 0.987) were found.Conclusion:
CYP2D6 allele frequencies were analyzed for the first time in a cohort from Uruguay. Results did not support any impact of CYP2D6 gene polymorphisms on clinical outcomes.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Tamoxifen
/
Breast Neoplasms
Limits:
Female
/
Humans
Language:
En
Journal:
Per Med
Year:
2023
Type:
Article
Affiliation country:
Uruguay